CRO's Stock Plummets Amid Accounting Investigation, Only Recovers 1% Today

ICON PLC (ticker: ICLR) shares closed at $99.70 on the New York Stock Exchange, up 1.68%. The company’s market capitalization is about $7.6 billion (roughly KRW 10 trillion), with a one-day gain of approximately $130 million (around KRW 1.7 trillion).

After ICON on February 12 disclosed an internal probe into the appropriateness of revenue recognition for fiscal years 2023–2025, its share price plunged about 49% in a single day. Uncertainty deepened as news emerged of investors preparing lawsuits over potential revenue overstatements and law firms launching their own investigations. (globenewswire.com)

Meanwhile, ICON is also strengthening its core business by expanding its oncology clinical-trial network—most recently opening a new cancer research center in Illinois. (investing.com)

Headquartered in Dublin, Ireland, ICON is a global contract research organization (CRO) that leverages healthcare intelligence to design and manage clinical trials for pharmaceutical and biotech companies in pre-launch drug development. (en.wikipedia.org)

Having grown in scale through its 2021 acquisition of U.S. CRO PRA Health Sciences, ICON now generates a significant portion of its revenue from the U.S. and Europe, making it particularly sensitive to U.S. economic conditions and the global biotech investment cycle. (en.wikipedia.org)